Causes of CIDP Exacerbation
CIDP exacerbations are primarily triggered by infections, with viral and bacterial pathogens being the most common precipitants, though the specific mechanisms remain incompletely understood. 1
Primary Triggers
Infectious Causes
The most well-documented triggers for CIDP exacerbations are infectious agents, which can precipitate both initial disease onset and subsequent relapses:
- Viral infections: Hepatitis B and C viruses, Cytomegalovirus, Epstein-Barr virus, and Human immunodeficiency virus have all been associated with CIDP exacerbations 1
- Bacterial infections: Mycoplasma pneumoniae and Bartonella henselae have been reported as triggers 1
These infections likely trigger exacerbations through molecular mimicry mechanisms, where pathogenic antigens cross-react with peripheral nerve components, reactivating the autoimmune response against myelin proteins.
Treatment-Related Exacerbations
Treatment-Related Fluctuations (TRFs)
TRFs occur in approximately 5% of CIDP patients and represent a distinct pattern of disease progression 2. These are defined as:
- Clinical deterioration occurring within 2 months following initial treatment-induced improvement or stabilization
- Distinguished from insufficient treatment response (which is not a true exacerbation)
- Indicate that treatment effect has worn off while inflammatory activity persists
When TRFs occur, repeat the full course of IVIg or plasma exchange, though evidence supporting this approach remains limited 2.
Progression to Acute-Onset CIDP
In approximately 5% of cases, repeated relapses suggest evolution to acute-onset CIDP, characterized by:
- Three or more TRFs, OR
- Clinical deterioration ≥8 weeks after disease onset 2
Immunotherapy-Related Considerations
While the provided evidence focuses on immune checkpoint inhibitor (ICI) therapy causing demyelinating polyneuropathies rather than CIDP exacerbations specifically, it's worth noting that immunomodulatory therapies can paradoxically trigger autoimmune neurologic complications 3. However, this applies to cancer immunotherapy rather than CIDP treatment itself.
Clinical Pitfalls
Do not confuse insufficient treatment response with true exacerbation - approximately 40% of CIDP patients fail to improve within 4 weeks of standard treatment, but this represents inadequate response rather than disease progression 2. True exacerbations require initial improvement followed by deterioration.
Monitor for infections vigilantly in CIDP patients, as they represent the most modifiable trigger for exacerbations. Any intercurrent infection should prompt consideration of temporary treatment intensification.
Unknown Factors
Despite advances in understanding CIDP pathophysiology, the specific triggering antigens and correlative antibodies remain undiscovered for most CIDP cases 4. The complex interplay between innate and adaptive immune systems makes predicting individual exacerbation triggers challenging 1, 4.